Novo Nordisk to cut U.S. GLP-1 drug prices by up to 50% in 2027
TL;DR Summary
Novo Nordisk said U.S. list prices for Wegovy, Ozempic, and Rybelsus will be cut by up to 50% to $675 per month starting Jan. 1, 2027, targeting insured patients with high-deductible plans or co-insurance and potentially lowering out-of-pocket costs; Medicare prices will also drop to $274 per month under the Inflation Reduction Act, aiming to boost access and competition in the GLP-1 market.
- Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients CNBC
- Novo Nordisk to slash Ozempic and Wegovy list prices by up to 50% for 2027 CNN
- Novo Nordisk cuts sticker price of weight-loss drugs Axios
- Novo to cut Ozempic and Wegovy prices amid intense competition USA Today
- Novo Will Slash US List Prices for Wegovy, Ozempic Next Year Bloomberg.com
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
3 min
vs 4 min read
Condensed
90%
611 → 63 words
Want the full story? Read the original article
Read on CNBC